Nepicastat
As of the edition of 20 October 2026, Nepicastat is a small molecule: stopped in 2009; acts on DBH.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2009
- Kind
- Small molecule
- Registered trials
- 3, 1 stopped early
- Disease areas
- Mental health; Chemically induced; Digestive system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| DBH | Dopamine beta-hydroxylase | P09172 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 1 | 0 | 0 | 0 |
| Phase 2 | 2 | 1 | 0 | 1 |
| All trials | 3 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Biotie Therapies | Lead sponsor of trials | 2008 to now |
| Jiangsu Yahong Meditech Co. Ltd aka Asieris | Lead sponsor of trials | 2023 to now |